Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium
Onco-Innovations (CBOE CA:ONCO) announced that its subsidiary, Inka Health, has received an Expression of Interest (EOI) from AstraZeneca to join as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium.
The PROmAI Consortium, led by Inka Health, aims to advance AI methodologies in oncology by combining real-world and clinical trial data with causal AI techniques. The initiative focuses on improving predictive modeling in cancer research, particularly during the transition from early- to late-phase clinical development.
AstraZeneca's involvement will include participation in the exploratory phase, encompassing joint planning discussions, project direction input, and strategic alignment around key use cases. Inka Health is currently in discussions with other global pharmaceutical companies for potential consortium participation.
Onco-Innovations (CBOE CA:ONCO) ha annunciato che la sua controllata, Inka Health, ha ricevuto una Manifestazione di Interesse (EOI) da parte di AstraZeneca per diventare membro fondatore del Consorzio PROmAI (Predictive Oncology Outcomes using Multimodal AI).
Il Consorzio PROmAI, guidato da Inka Health, mira a sviluppare metodologie di intelligenza artificiale in oncologia combinando dati real-world e di studi clinici con tecniche di AI causale. L'iniziativa si concentra sul miglioramento della modellizzazione predittiva nella ricerca sul cancro, specialmente nel passaggio dalla fase precoce a quella avanzata dello sviluppo clinico.
La partecipazione di AstraZeneca includerà la fase esplorativa, comprendente discussioni congiunte di pianificazione, contributi alla direzione dei progetti e allineamento strategico su casi d'uso chiave. Inka Health è attualmente in trattative con altre aziende farmaceutiche globali per una possibile partecipazione al consorzio.
Onco-Innovations (CBOE CA:ONCO) anunció que su subsidiaria, Inka Health, ha recibido una Expresión de Interés (EOI) de AstraZeneca para unirse como miembro fundador del Consorcio PROmAI (Predictive Oncology Outcomes using Multimodal AI).
El Consorcio PROmAI, liderado por Inka Health, tiene como objetivo avanzar en las metodologías de inteligencia artificial en oncología combinando datos del mundo real y de ensayos clínicos con técnicas de IA causal. La iniciativa se enfoca en mejorar la modelización predictiva en la investigación del cáncer, especialmente durante la transición de las fases tempranas a las avanzadas del desarrollo clínico.
La participación de AstraZeneca incluirá la fase exploratoria, que abarca discusiones conjuntas de planificación, aportes a la dirección del proyecto y alineación estratégica en casos de uso clave. Inka Health está actualmente en conversaciones con otras compañías farmacéuticas globales para una posible participación en el consorcio.
Onco-Innovations (CBOE CA:ONCO)는 자회사 Inka Health가 AstraZeneca로부터 다중 모달 AI를 활용한 예측 종양학 결과(PROmAI) 컨소시엄의 창립 멤버로 참여하겠다는 관심 표명(EOI)을 받았다고 발표했습니다.
PROmAI 컨소시엄은 Inka Health가 주도하며, 실제 데이터와 임상 시험 데이터를 인과 AI 기법과 결합하여 암 연구에서 AI 방법론을 발전시키는 것을 목표로 합니다. 이 이니셔티브는 초기 단계에서 후기 임상 개발로 전환하는 과정에서 예측 모델링을 개선하는 데 중점을 둡니다.
AstraZeneca의 참여는 공동 기획 논의, 프로젝트 방향성 제공, 주요 활용 사례에 대한 전략적 조율을 포함하는 탐색 단계에 포함됩니다. 현재 Inka Health는 다른 글로벌 제약사들과도 컨소시엄 참여 가능성에 대해 논의 중입니다.
Onco-Innovations (CBOE CA:ONCO) a annoncé que sa filiale, Inka Health, a reçu une Expression d'Intérêt (EOI) de la part de AstraZeneca pour rejoindre en tant que membre fondateur le Consortium PROmAI (Predictive Oncology Outcomes using Multimodal AI).
Le Consortium PROmAI, dirigé par Inka Health, vise à faire progresser les méthodologies d'IA en oncologie en combinant des données du monde réel et des essais cliniques avec des techniques d'IA causale. L'initiative se concentre sur l'amélioration de la modélisation prédictive dans la recherche sur le cancer, notamment lors de la transition entre les phases précoces et tardives du développement clinique.
La participation d'AstraZeneca inclura la phase exploratoire, comprenant des discussions conjointes de planification, des apports à la direction du projet et un alignement stratégique autour des cas d'utilisation clés. Inka Health est actuellement en pourparlers avec d'autres entreprises pharmaceutiques mondiales pour une éventuelle participation au consortium.
Onco-Innovations (CBOE CA:ONCO) gab bekannt, dass seine Tochtergesellschaft Inka Health eine Interessenbekundung (EOI) von AstraZeneca erhalten hat, um als Gründungsmitglied dem PROmAI-Konsortium (Predictive Oncology Outcomes using Multimodal AI) beizutreten.
Das vom Inka Health geführte PROmAI-Konsortium verfolgt das Ziel, KI-Methoden in der Onkologie voranzutreiben, indem reale Daten und klinische Studiendaten mit kausalen KI-Techniken kombiniert werden. Die Initiative konzentriert sich darauf, die prädiktive Modellierung in der Krebsforschung zu verbessern, insbesondere beim Übergang von frühen zu späten Phasen der klinischen Entwicklung.
Die Beteiligung von AstraZeneca umfasst die explorative Phase, einschließlich gemeinsamer Planungsdiskussionen, Beiträge zur Projektleitung und strategische Abstimmung zu wichtigen Anwendungsfällen. Inka Health führt derzeit Gespräche mit weiteren globalen Pharmaunternehmen über eine mögliche Beteiligung am Konsortium.
- Strategic partnership with major pharmaceutical company AstraZeneca validates Inka Health's AI technology and approach
- Potential for expanded collaboration network with other global pharmaceutical companies
- Initiative positions Inka Health as a leader in oncology-focused AI development
- None.
VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. ("Inka Health"), has received a formal Expression of Interest (EOI) from AstraZeneca plc (AstraZeneca), indicating its intent to participate as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium. PROmAI is being established as a strategic initiative to bring together leading global pharmaceutical companies and scientific experts to guide and inform Inka Health's development of next-generation AI solutions in oncology. AstraZeneca's involvement would reinforce the Consortium's vision of creating a high-impact, multi-stakeholder platform shaping the future of predictive cancer research.
The PROmAI Consortium, initiated and led by Inka Health, is a collaborative initiative focused on advancing the development and validation of artificial intelligence methodologies to support improved prediction of oncology outcomes. Designed to address current limitations in translational modeling, particularly during the transition from early- to late-phase clinical development, the Consortium aims to bring together insights from pharmaceutical, data science, and clinical research communities. Inka Health is in active discussions with additional global pharmaceutical companies regarding potential participation in the Consortium and will provide further updates as progress is made.
By combining real-world and clinical trial data-including molecular, clinical, imaging, and other multimodal datasets-with emerging techniques in causal AI, the Consortium seeks to foster innovation in predictive modeling, enhance interpretability and reliability of results, and contribute to frameworks aligned with regulatory and payer expectations. Participating members will collaborate on the design and execution of research activities that support the broader goal of improving trust, transparency, and utility of AI-driven insights in oncology drug development. For Inka Health, this Consortium represents a strategic opportunity to lead the advancement of AI methodologies in oncology.
Through the EOI, AstraZeneca has expressed its intention to participate in the Consortium's exploratory phase, which will include joint planning discussions, early input into project direction, and strategic alignment around key use cases. The collaboration is expected to evolve over time, with the potential for broader participation in research publications, workshops, and future initiatives that advance the Consortium's scientific mission.
Onco-Innovations views this Expression of Interest as a strong validation of the PROmAI initiative's relevance and potential impact in the rapidly evolving field of oncology R&D. The Company remains committed to fostering cross-sector collaboration to unlock the transformative potential of artificial intelligence in clinical innovation.
"This is not just about proving that AI can work in oncology-it's about shaping how it should work in ways that matter to regulators, clinicians, and ultimately patients. Having AstraZeneca engage at this early stage signals a shared commitment to advancing practical, credible AI applications in one of medicine's most complex domains. As leaders in this space, we see PROmAI not only as a research initiative but as a foundation for setting standards around trust, utility, and translational impact in oncology-focused AI," stated Paul Arora, CEO of Inka Health.
About Inka Health
Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data-including genomics, transcriptomics, and proteomics-SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health helps pharmaceutical companies accelerate drug deve0lopment, reduce trial failures, and bring life-saving therapies to market faster.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, PROmAI, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies, the failure to realize the anticipated benefits of PROmAI and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
What is the PROmAI Consortium announced by Onco-Innovations (ONNVF)?
What is AstraZeneca's role in Onco-Innovations' PROmAI Consortium?
How will the PROmAI Consortium benefit oncology research?
What types of data will Onco-Innovations' PROmAI Consortium analyze?
Who can join Onco-Innovations' PROmAI Consortium?
